Skip to main content

Invalidity and Non- infringement.

"Invalidity" and "non-infringement" are two important concepts in patent law, often considered in the context of patent disputes or litigation.

1:Invalidity refers to the legal determination that a patent is not valid, meaning that it should not have been granted in the first place. A patent can be invalidated for various reasons, such as:

- Lack of Novelty: The invention was not new or was publicly disclosed before the patent filing.-

-Lack of Inventive Step (Obviousness): The invention would have been obvious to a person skilled in the relevant field.

-Lack of Industrial Applicability: The invention does not have a practical and useful application.

-Insufficient Description (Lack of Enablement): The patent specification does not enable a person skilled in the art to carry out the invention.-

-Violation of Patent Requirements: The patent application did not meet certain formal or procedural requirements.

If a court or a relevant authority determines that a patent is invalid, it means that the patent holder's exclusive rights are no longer enforceable, and the patent may be revoked.

2.Non-Infringement:Non-infringement refers to the situation where a product, process, or service does not infringe on the valid claims of a patent. In other words, the accused product or process falls outside the scope of protection defined by the patent's claims.

To establish non-infringement, the accused party typically shows that their product or process does not include each element or limitation of the patented claims or that it employs a substantially different technology or approach.

If a court finds that the accused product or process does not infringe on the valid claims of the patent, the patent holder cannot assert infringement claims against that particular product or process.

Both concepts play a crucial role in patent litigation and disputes, and the determination of either invalidity or non-infringement can significantly impact the outcome of a case. It is essential to consult with legal experts, such as patent attorneys, when dealing with patent-related matters to fully understand and protect your rights.

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em

Novo Nordisk settles with 2 Florida venders of compounded (Semaglutide)Ozempic:

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing

Hypertension-An Overview

INTRODUCTION: Systemic arterial hypertension is one of the strongest known modifiable risk factors for ischaemic heart disease, stroke, renal failure and heart failure. It remains poorly treated. As an asymptomatic disorder, people are understandably reluctant to accept adverse drug effects in addition to the inconvenience of long-term treatment. In this regard, modern drugs represent an enormous improvement. PATHOPHYSIOLOGY AND SITES OF DRUG ACTION Hypertension is occasionally secondary to some distinct disease. However, most patients with persistent arterial hypertension have essential hypertension. Arterial blood pressure is determined by cardiac output, peripheral vascular resistance and large artery compliance. Peripheral vascular resistance is determined by the diameter of resistance vessels (small muscular arteries and arterioles) in the various tissues. One or more of a ‘mosaic’ of interconnected predisposing factors (including positive family history, obesity and phys